Biocytogen-B (HKEX: 02315) rose more than 6% intraday before settling at a gain of 3.85% at HK$52.55 as of press time, with turnover of HK$24.9591 million.
In the first half of 2026, Biocytogen-B reported operating revenue of RMB 941 million, up 51.60% year-on-year, while net profit attributable to shareholders reached RMB 241 million, up 402.29% year-on-year. Non-GAAP net profit attributable to shareholders came in at RMB 197 million, up 591.53% year-on-year.
Notably, in the first half of 2026, the company's preclinical products and services business, centered on the sale of innovative animal models, generated operating revenue of RMB 723 million, up 57.94% year-on-year, with a gross margin of 75.22%. Within this segment, the model animal business contributed revenue of RMB 446 million, up 62.44% year-on-year, with a gross margin of 82.30%.
Western Securities noted that Biocytogen-B continues to upgrade its "Thousand Mice, Ten Thousand Antibodies" initiative. To date, the company has completed evaluation and research on approximately 1,200 targets and has essentially conducted antibody development for all targets, forming an antibody molecule sequence "shelf" of over one million antibody molecules with diverse binding epitopes. In May 2026, the company officially launched its next-generation AI-driven antibody discovery platform, RenSuper Workstation, successfully building a triple-driven architecture of a "real antibody sequence library + AI + automated intelligent manufacturing platform."
Comments